Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP exerts significant effects against chemoresistant pancreatic tumor cells, as reported by one of the Company’s joint researchers, Mrs. Belén Toledo Cutillas MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén, Granada, Spain.

Laboratory studies by qPCR (quantitative polymerase chain reaction), along with western and immunofluorescence analyses, confirm downregulation of chemoresistant genes expression in chemoresistant tumor cells treated with PRP, compared with tumor cells and untreated chemoresistant tumor cells as experimental controls. Mrs. Cutillas believes the results are “fantastic” and corroborate her research into the effects of PRP as a chemosensitizing agent against pancreatic cancer, and the influence of PRP on the tumor microenvironment.

Dr Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer said, “Resistance to standard chemotherapy is a significant problem for pancreatic cancer sufferers with a poor prognosis. The work undertaken with our joint research partners confirms PRP effects the tumor microenvironment and suppresses chemoresistant genes in pancreatic tumor cells. This means not only can PRP prevent tumor formation, which leads to drug resistance, but also it alters the signaling pathways to eliminate this possibility. PRP is a unique approach because, rather than inhibiting a specific gene target, it re-educates these cells to overcome tumor resistance. This could have tremendous implications for PRP as a chemosensitizer agent with standard treatment approaches to generate better clinical outcomes for pancreatic cancer patients. We look forward to working with our joint research partners to better understand these applications for PRP as we advance towards Phase I and II clinical studies.”

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.

The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

To view the Company’s “Mechanism of Action” video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target,” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties, and other factors, that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern absent new debt or equity financings; the Company’s current reliance on substantial debt financing that, as of the date of this press release, it would have substantial difficulty repaying in cash; the Company’s ability successfully to remediate material weaknesses in its internal controls; the Company’s ability to reach research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms on an as-needed basis; the Company’s ability successfully to initiate and complete clinical trials and to develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and finance expertise; the Company’s dependence on third parties for services; the Company’s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions; competition; and other risks, including, but not limited to, those described in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005332/en/

Investor Relations and Media:
Mr. James Nathanielsz
Propanc Biopharma, Inc.
irteam@propanc.com
+61-3-9882-0780

Source: Propanc Biopharma, Inc.

Released March 16, 2023